Brett Hall, PhD

Brett Hall, Ph.D. joined Immuneering as Chief Scientific Officer in 2019. Prior to Immuneering, he served as Chief Executive Officer of Asellus Therapeutics, and Head of Translational Medicine of Oncology at Medimmune, the biologics division of AstraZeneca. Dr. Hall also held roles of increasing responsibility at Johnson & Johnson, culminating in his role as Head of Biomarkers of the Hematologic Disease Area Stronghold, where he led clinical translational efforts for Sylvant® and Imbruvica®. He has extensive drug development and leadership experience ranging from early drug discovery through translational clinical sciences, including multiple drug registrations. Dr. Hall has extensively published in the areas of tumor microenvironment (TME) and translational sciences and holds multiple patents for drug pharmacology and discovery. Before joining industry, Dr. Hall was an Assistant Professor at Ohio State University focused on the development of human TME-aligned models to enable improved clinical translation. He also served in the U.S. Air Force and worked as an investment banker. Dr. Hall received his B.S. in biochemistry from Ohio State University, his Ph.D. in immunology and cancer biology from West Virginia University and completed his post-doctoral fellowship in cancer cell epigenetics at St. Jude Children’s Research Hospital.